MENTSH analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
1. A composition comprising: a peptide comprising the amino acid sequence of SEQ ID NO: 97, the amino acid sequence with about 70% or more percent identity to SEQ ID NO: 97, or the amino acid sequence set forth in any of SEQ ID NOs: 1-22, 25-36, 43-47, 49-63, 65-87, 89, 91-93, and 95, wherein the peptide is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 amino acids in length.
2. The composition of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO:97.
3. The composition of claim 1 , wherein the peptide consists of the amino acid sequence of any one of SEQ ID NOs: 1-22, 25-36, 43-47, 49-63, 65-87, 89, 91-93, and 95.
4. The composition of claim 1 , wherein the peptide contains a negatively charged amino acid as a substitute for residue threonine-7, residue serine-11, residue tyrosine-16, or a combination thereof of SEQ ID NO:97.
5. The composition of claim 1 , wherein the peptide comprises a post-translational or artificial modification.
6. The composition of claim 5 , wherein the artificial modification comprises pegylation, fatty-acid conjugation, polypeptide extension, Immunoglobulin G fragment crystallizable region (IgG-Fc), carnitine palmitoyltransferase (CPT), human serum albumin (HSA), elastin-like polypeptide (ELP), transferrin, or albumin modification.